



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/085,476	02/27/2002	Raffaele De Francesco	IT0002PCA	5843

210 7590 01/26/2005

MERCK AND CO., INC  
P O BOX 2000  
RAHWAY, NJ 07065-0907

EXAMINER

HUTSON, RICHARD G

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 01/26/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

10/085,476

Applicant(s)

DE FRANCESCO ET AL.

Examiner

Richard G. Hutson

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 15 November 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 8-15, 17 and 18 is/are pending in the application.
- 4a) Of the above claim(s) 8-11 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 12-15, 17 and 18 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>11/2004</u> . | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/15/2004 has been entered.

Applicants amendment of claims 12 and cancellation of claims 16 and 19, in the paper of 11/15/2004, is acknowledged. Claims 8-15, 17 and 18 are still at issue and are present for examination.

Applicants' arguments filed on 11/15/2004, have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Claims 8-11 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

### ***Information Disclosure Statement***

Applicants filing of the supplemental information disclosure statement filed on 11/15/2004, is acknowledged. Those references considered have been initialed on the form 1449.

***Claim Rejections - 35 USC 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 12, 14, 17 and 18 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Tomei et al. (Journal of Virology 67(7): 4017-4026, July 1993).

The rejection was stated in the previous office action and repeated below.

Tomei et al. teach that the Hepatitis C virus (HCV) is considered to be the major etiologic agent of post-transfusion non-A, non-B hepatitis and that the NS5 region of the HCV polyprotein is cleaved into two smaller products of 47 and 65 kDa. Tomei et al. also teach that the NS5B region contains a GDD sequence characteristic of RNA-dependent RNA polymerases (RdRp) and they suggest that this protein may act as a viral RNA replicase during HCV-specific RNA synthesis and also function in the replication of the viral genome, acting as a component of the replication complex involved in the reaction (page 4024, column 1, paragraph 5). Tomei et al. further teach DNA constructs and transient expression of the HCV genome and characterize the post-translational processing of the HCV transcript, and specifically transcribe and translate NS5B, described by SEQ ID NO: 1. (see page 4020, Figure 1 and also Figure 3A).

One of ordinary skill in the art at the time of the filing of the invention would have been motivated to incubate together the HCV NS5B protein, ribonucleotide substrates and a RNA template under conditions suitable to produce RNA-dependent RNA polymerase, wherein said incubation takes place *in vitro* in order to further characterize the function and role of the protein(s) encoded by the NS5B ORF. The expectation of success comes from the high degree of skill in the art with respect to protein expression, as demonstrated by Tomei et al. in their expression of the HCV cDNA encoding the entire polyprotein using a vaccinia virus T7 expression system. One of ordinary skill at the time of invention would have been motivated to produce the NS5B protein both by the independent transcription and translation of the NS5B as well as by the proteolytic processing of the NS2-NS3-NS4-NS5 polyprotein to determine if the proteolytic processing event affects the activity of the NS5B protein product. One would have been further motivated to vary the RNA templates and primers in the incubation mixture to characterize the specific mechanism of action of any RNA-dependent RNA polymerase activity. The motivation for the addition of ribonucleotide substrates and a RNA template comes from the suggestion by Tomei et al. that the NS5B encodes a RNA-dependent RNA polymerase. The reasonable expectation of success comes from the teaching of Tomei et al. that while the nonstructural region of the HCV genome has not been characterized in detail, it is thought to be processed in a manner similar to that of flaviviruses and pestiviruses and the hydropathy profile of HCV polyprotein is similar to that of the flavivirus polyprotein as well as the suggestion that the NS5B ORF encoded protein is a RNA-dependent RNA polymerase. One of ordinary skill in the art

Art Unit: 1652

at the time of filing of the application would have been further motivated to incubate together the HCV NS5B protein, ribonucleotide substrates and a RNA template under conditions suitable to produce RNA-dependent RNA polymerase activity, wherein said incubation takes place *in vitro* in the presence of potential target molecules which may inhibit the action of the NS5B protein as a means of identifying potential therapeutics to be used against the NS5B protein and HCV. The motivation for why one of skill in the art would be interested in the function of the NS5B ORF is because as one of only a few HCV encoded nonstructural proteins the protein(s) encoded by the NS5B ORF is a prime target for the development of therapeutics against HCV. A reasonable expectation of success comes from the high degree of knowledge in the art with respect to protein expression and the identification of inhibitors of said proteins activity, as discussed above.

In response to the previous rejection, applicants have amended claim 12 (claims 14, 17 and 18 dependent on) and traverse the rejection as it applies to the newly amended claims.

Applicants traverse the rejection on the basis that applicants have amended claim 12 to further describe the HCV NS5B as a "purified HCV NS5B recombinant protein" as well as "was expressed in either a eukaryotic or prokaryotic heterologous system and purified to apparent homogeneity". Applicants further submit that the references cited merely speculate as to a possible role of NS5B in providing polymerase activity and that there is further uncertainty as to whether NS5B, if it encodes the polymerase, can be successfully recombinantly expressed, purified to apparent

Art Unit: 1652

homogeneity and then used in an *in vitro* assay to generate sufficient activity to identify inhibitors.

Applicants complete argument is acknowledged, however, found non-persuasive for the reasons stated previously and below.

With respect to applicants assertion that Tomei et al. is uncertain as to whether NS5B, if it encodes the polymerase, can be successfully recombinantly expressed, purified to apparent homogeneity and then used in an *in vitro* assay to generate sufficient activity to identify inhibitors, as stated previously, Tomei et al. teach that the NS5B region contains a GDD sequence characteristic of RNA-dependent RNA polymerases (RdRp) and they suggest that this protein may act as a viral RNA replicase during HCV-specific RNA synthesis and also functions in the replication of the viral genome and Tomei et al. express the NS5B protein as part of a polyprotein recombinantly. The high degree of knowledge in the art as well as that taught by Tomei et al. further would suggest that the NS5B could be purified to apparent homogeneity and then used in an *in vitro* assay to generate sufficient activity to identify inhibitors. As previously stated, the expectation of success of such is based on in addition to that taught by Tomei et al. the high level of skill in the art with respect to the recombinant expression of proteins, their identification and the identification of inhibitors of the identified activity (i.e. RNA-dependent RNA polymerase activity).

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the

Art Unit: 1652

unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

As previously stated, claims 12–15, 17 and 18 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 8-15 of U.S. Patent No. 6,383,768. An obvious type double patenting rejection is appropriate where conflicting claims are not identical, but an examined application claim is not patentably distinct from the reference claim(s) because the claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

Although the conflicting claims are not identical, they are not patentably distinct from each other because claims 8-15 of U.S. Patent No. 6,383,768 drawn to a method for measuring the ability of a compound to affect hepatitis C virus (HCV) NS5B activity comprising: (a) incubating in vitro a composition comprising HCV NS5B, ribonucleotide substrates, an RNA template, and said compound, under conditions suitable to produce NS5B RNA-dependent RNA polymerase activity, wherein said NS5B is provided to said



Art Unit: 1652

composition from a preparation wherein said NS5B is the only HCV protein present and (b) measuring the ability of said compound to affect said NS5B RNA-dependent RNA polymerase activity anticipates claims 12, 14, 16, 17 and 18 of the instant application.

Applicants acknowledgement of this rejection is noted.

The rejection of claims 13, 15 and 19 under 35 U.S.C. 101 as claiming the same invention as that of claims 8, 15 and 11 of prior U.S. Patent No. 6,383,768 is hereby withdrawn based on applicants traversal, however, these claims are included in the above obviousness-type double patenting as being unpatentable over claims 8-15 of U.S. Patent No. 6,383,768 for the reasons previously stated for claims 12, 14, 16, 17 and 18.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G Hutson whose telephone number is (571) 272-0930. The examiner can normally be reached on 7:30 am to 4:00 pm, M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (571) 272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, appearing to read 'R. G. Hutson', with a large, sweeping flourish at the end.

Richard G Hutson, Ph.D.  
Primary Examiner  
Art Unit 1652

rg  
1/20/2005